We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization ImmunoTherapy, or CODITTM, is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure, or reduce symptom severity should an allergic reaction occur. CODIT is intended to reduce meaningfully the burden and anxiety experienced by food-allergic patients and their families.
Type | Public | |
Founded | 2011 | |
HQ | Brisbane, CA, US | Map |
Website | aimmune.com | |
Employee Ratings | More | |
Overall Culture | A+ | More |
USD | |
---|---|
Net income (Q2, 2020) | (69.2m) |
EBIT (Q2, 2020) | (66.0m) |
Market capitalization (16-Oct-2020) | 2.3b |
Closing stock price (16-Oct-2020) | 34.5 |
Cash (30-Jun-2020) | 266.6m |
EV | 2.1b |
USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 58.5m | 112.7m | 65.0m | 74.4m | 76.9m | 78.7m | 84.5m | 73.8m | 209.3m | 142.2m | 78.4m | 81.1m | 72.6m | 76.8m | 298.4m | 266.6m |
Accounts Receivable | 772.0k | 25.0k | ||||||||||||||
Prepaid Expenses | 2.1m | 1.2m | 5.0m | 3.8m | 2.3m | 2.6m | 5.3m | 6.1m | 8.4m | 6.8m | 6.5m | 8.2m | 6.9m | 6.8m | 4.6m | 4.0m |
Inventories | 4.1m | 5.6m |
USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (10.8m) | (19.8m) | (15.5m) | (33.7m) | (55.7m) | (25.9m) | (58.4m) | (90.2m) | (49.5m) | (102.1m) | (153.8m) | (54.3m) | (117.1m) | (181.6m) | (86.4m) | (155.7m) |
Depreciation and Amortization | 30.0k | 60.0k | 125.0k | 257.0k | 393.0k | 144.0k | 387.0k | 703.0k | 356.0k | 738.0k | 1.1m | 666.0k | 1.8m | 2.9m | 1.3m | 2.7m |
Inventories | (4.0m) | (9.0m) | ||||||||||||||
Accounts Payable | (169.0k) | 536.0k | (78.0k) | (645.0k) | (393.0k) | 249.0k | 883.0k | 2.9m | (431.0k) | 2.6m | 8.1m | 1.9m | 5.5m | 4.3m | 191.0k | 1.4m |
USD | Q2, 2015 |
---|---|
Financial Leverage | 1.1 x |
Aimmune Therapeutics has 1.56k Twitter Followers. The number of followers has decreased 0.7% month over month and decreased 1% quarter over quarter
691
Tweets
292
Following
1.6k
Followers
1
Tweets last 30 days
30
Avg. likes per Tweet
100%
Tweets with engagement
A+
90/100
A+
85/100
A+
92/100
When was Aimmune Therapeutics founded?
Aimmune Therapeutics was founded in 2011.
Who are Aimmune Therapeutics key executives?
Aimmune Therapeutics's key executives are Andrew Oxtoby, Eric Bjerkholt and Samina Bari.
How many employees does Aimmune Therapeutics have?
Aimmune Therapeutics has 275 employees.
Who are Aimmune Therapeutics competitors?
Competitors of Aimmune Therapeutics include Inovio Pharmaceuticals, Emisphere Technologies and Intercept Pharmaceuticals.
Where is Aimmune Therapeutics headquarters?
Aimmune Therapeutics headquarters is located at 8000 Marina Blvd #200, Brisbane.
Where are Aimmune Therapeutics offices?
Aimmune Therapeutics has offices in Brisbane, Durham, München, Dublin and in 1 other location.
How many offices does Aimmune Therapeutics have?
Aimmune Therapeutics has 5 offices.
Receive alerts for 300+ data fields across thousands of companies